Biotech | August 16, 2022
PharmaCyte Biotech reaches cooperation agreement with Iroquois Capital
Company appoints five new independent directors to reconstituted board
Company appoints five new independent directors to reconstituted board
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
Man lost 54 Kgs in 6 months with MGB procedure
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Subscribe To Our Newsletter & Stay Updated
